Reckitt Benckiser Group plc (RBGPF)
| Market Cap | 44.00B -12.7% |
| Revenue (ttm) | 18.09B -3.1% |
| Net Income | 3.82B +115.6% |
| EPS | 5.88 +121.8% |
| Shares Out | n/a |
| PE Ratio | 11.53 |
| Forward PE | 14.71 |
| Dividend | 1.21 (1.68%) |
| Ex-Dividend Date | Aug 6, 2026 |
| Volume | 851 |
| Open | 71.34 |
| Previous Close | 72.16 |
| Day's Range | 71.34 - 71.34 |
| 52-Week Range | 58.67 - 90.71 |
| Beta | 0.26 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 29, 2026 |
About Reckitt Benckiser Group
Reckitt Benckiser Group plc manufactures and sells health, hygiene, and nutrition products in the United Kingdom and internationally. The company offers germ protection under Dettol name; intimate wellness under Durex and KY brand names; over the counter under the Biofreeze, Gaviscon, Mucinex, Nurofen, Delsym, Cepacol, and Strepsils names. It also provides personal care products under Clearasil and Veet brand names; vitamins, minerals, and supplements under MegaRed, Airborne, Digestive-Advantage, Movefree, and neuriva names; stain removal under... [Read more]
Financial Performance
In 2025, Reckitt Benckiser Group's revenue was 14.21 billion, an increase of 0.25% compared to the previous year's 14.17 billion. Earnings were 3.18 billion, an increase of 123.14%.
Financial numbers in GBP Financial StatementsNews
Reckitt Announces Expiration and Results of Any and All Tender Offer and Consent Solicitation for Mead Johnson Nutrition Company Notes due 2044
SLOUGH, United Kingdom, Aug. 14, 2026 /PRNewswire/ -- Reckitt Benckiser Group plc ("Reckitt") (LSE: RKT) announced today (i) the expiration and results of its wholly-owned subsidiary, Mead Johnson Nut...
Reckitt Benckiser Group Earnings Call Transcript: H1 2026
Group delivered 2.6% like-for-like net revenue growth in H1 2026, with Q2 accelerating to 4.7%. Innovation, emerging markets, and portfolio focus drove performance, while over GBP 3 billion was returned to shareholders. Full-year guidance for 4%-5% growth and margin targets remain unchanged.
Reckitt Benckiser Group Quarterly report: H1 2026
Reckitt Benckiser Group has published its H1 2026 quarterly earnings report on July 29, 2026.
Reckitt Benckiser Group Slides: H1 2026
Reckitt Benckiser Group has posted slides in relation to its H1 2026 quarterly earnings report, which was published on July 29, 2026.
Lysol Maker Reckitt Issues New $664 Million Share Buyback
The Lysol, Mucinex and Durex-condom maker issued a new share buyback program after reporting 4.7% like-for-like net revenue, bolstered by growth in emerging markets.
Reckitt beats second-quarter sales estimates on emerging markets strength
Dettol maker Reckitt beat second-quarter sales growth estimates and reaffirmed its annual forecast on Wednesday, as strong demand in China, India and other emerging markets helped offset weakness in...
Lysol Maker Reckitt to Offload Sanctions-Hit Russian Hygiene Business
The deal with Russia's Arnest Management—which manufactures cosmetics and household goods—is expected to complete during the second half of 2026.
UK's Reckitt to sell Russian hygiene business
Britain's Reckitt Benckiser Group said on Friday that it has agreed to divest its Russian hygiene business to Arnest Management LLC for an undisclosed sum.
Reckitt Benckiser upgraded to Buy from Hold at Jefferies
Jefferies analyst David Hayes upgraded Reckitt Benckiser (RBGLY) to Buy from Hold with a price target of 5,900 GBp, up from 5,600 GBp. Sanctions on Russia Household products, regulatory intervention…
Missouri jury sides with Enfamil maker Mead Johnson in case over preterm baby formula
A jury in St. Louis on Thursday rejected claims that Reckitt unit Mead Johnson's specialized formula for preterm babies was to blame for causing an infant's dangerous bowel disease.
Reckitt Benckiser price target lowered to 5,400 GBp at Deutsche Bank
Deutsche Bank analyst Tom Sykes lowered the firm’s price target on Reckitt Benckiser (RBGLY) to 5,400 GBp from 5,430 GBp and keeps a Hold rating on the shares. Published first…
Reckitt Benckiser price target lowered to 5,800 GBp at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Reckitt Benckiser (RBGLY) to 5,800 GBp from 6,200 GBp and keeps an Overweight rating on the shares.
Reckitt Benckiser Group Transcript: Investor update
Digital science and AI are transforming all stages of innovation, driving faster, larger, and more successful product launches, with tangible impacts on growth, cost savings, and sustainability. Proprietary data, advanced platforms, and a global upskilling effort underpin a robust, differentiated pipeline and operational efficiency.
Reckitt Benckiser price target lowered to 6,200 GBp from 7,000 GBp at Citi
Citi lowered the firm’s price target on Reckitt Benckiser (RBGLY) to 6,200 GBp from 7,000 GBp and keeps a Buy rating on the shares.
Reckitt stock dips on Q1 miss: what's really ailing the health giant?
Reckitt stock fell about 5% in early trading on Wednesday after the consumer goods group said first-quarter core like-for-like net revenue rose only 1.3%. The figure was well below the 2.9% analysts h...
Reckitt Benckiser Group Earnings Call Transcript: Q1 2026
Core Reckitt delivered 1.3% like-for-like net revenue growth in Q1, with 3.1% growth excluding seasonal business, led by strong performance in China and India. Full-year guidance for 4%-5% growth and higher margins is maintained, despite ongoing geopolitical and input cost headwinds.
Reckitt Benckiser Group Quarterly report: Q1 2026
Reckitt Benckiser Group has published its Q1 2026 quarterly earnings report on April 22, 2026.
Reckitt's Like-for-Like Revenue Rises on Emerging Markets Performance
Lysol maker Reckitt Benckiser booked a rise in first-quarter like for like revenue, helped by strong emerging markets performance, where like-for-like sales grew 7.6%.
Reckitt misses revenue forecast, warns on margins on oil price shock
Reckitt missed quarterly like-for-like revenue forecasts and warned of lower first-half margins, citing high oil prices and a weak cold and flu season, knocking the Dettol maker's shares as much as 7...
Reckitt Benckiser upgraded to Buy from Hold at Kepler Cheuvreux
Kepler Cheuvreux analyst Karel Zoete upgraded Reckitt Benckiser (RBGLY) to Buy from Hold with a 6,000 GBp price target The firm views the post-earnings selloff as overdone. Published first on…
Reckitt Benckiser price target lowered to 6,200 GBp at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Reckitt Benckiser (RBGLY) to 6,200 GBp from 6,300 GBp and keeps an Overweight rating on the shares.
Reckitt Benckiser price target lowered to 5,460 GBp at Deutsche Bank
Deutsche Bank lowered the firm’s price target on Reckitt Benckiser (RBGLY) to 5,460 GBp from 5,500 GBp and keeps a Hold rating on the shares.
Reckitt Benckiser upgraded to Overweight from Equal Weight at Morgan Stanley
Morgan Stanley upgraded Reckitt Benckiser (RBGLY) to Overweight from Equal Weight with a price target of 6,300 GBp, down from 6,500 GBp. The firm says the current share price does…
Reckitt Benckiser Group Transcript: UBS Global Consumer and Retail Conference
Emerging markets, especially China, drove significant growth through focused leadership and digital innovation, while mature markets like Europe face flat growth and North America is set for recovery in 2026. Margin expansion is targeted via operational efficiencies, portfolio transformation, and increased R&D and AI investments.
Reckitt Benckiser price target lowered to 5,479 GBp from 5,647 GBp at Berenberg
Berenberg lowered the firm’s price target on Reckitt Benckiser (RBGLY) to 5,479 GBp from 5,647 GBp and keeps a Hold rating on the shares.